

## 510(k) Summary<sup>1</sup>

SEP 19 2011

(a) (1) Submitter's name, address  
 Bionostics, Inc.  
 7 Jackson Road  
 Devens, MA 01434

Contact Person  
 Randy Byrd  
 VP, Chief Technical Officer  
 (978) 772-7070 x 272

Date of preparation of this summary: 15 August 2011

(2) Device trade or proprietary name: Glucose Meter-Check Control for AgaMatrix

Device common or usual name or classification name:

JJX Single (Specified) Analyte Control, All Types, Assayed and Unassayed

REGULATION MEDICAL SPECIALTY	REGULATION NUMBER	CLASS	REGULATION DESCRIPTION
Chemistry	862.1660	II	Glucose Control

### I. Substantial Equivalence

Glucose Meter-Check Control Solution for AgaMatrix substantially equivalent in function, safety and efficacy to currently marketed devices for the same intended use as shown in the following tables:

Characteristic	Predicate Device	Modified Device
Name:	WaveSense Control Solution	Glucose Meter-Check Control Solution for AgaMatrix
510(k), Date:	K052762, Jan 23 2006	
Number of levels:	2, typical fasting glucose and high, elevated blood glucose	1, typical fasting glucose
Target ranges:	111-169 and 298-448 mg/dL glucose	105-158 mg/dL glucose
Analytes:		
Container:	6 mL LDPE vial with dispensing tip and cap	6 mL LDPE vial with dispensing tip and cap
Fill volume:	4 mL	4 mL
Color:	blue	blue
Matrix:	Buffered, aqueous solution of D-Glucose, viscosity modifier, preservatives and other, non-reactive ingredients.	Buffered, aqueous solution of D-Glucose, viscosity modifier, preservatives and other, non-reactive ingredients.
Brands:	WaveSense	Glucose Meter-Check

<sup>1</sup> This summary of safety and effectiveness is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

**II. Description of the new device**

Glucose Meter-Check Control Solution for AgaMatrix is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The Glucose Meter-Check Control Solution is formulated for optimal performance on AgaMatrix glucose meters utilizing the WaveSense family of test strips.

**(a) (1) Intended use of the device**

The Glucose Meter-Check Control Solution for AgaMatrix is intended for use to verify the performance and correct operation of the AgaMatrix blood glucose monitoring test systems utilizing the WaveSense family of blood glucose test strips. Glucose Meter-Check Control Solution for AgaMatrix is intended for use by healthcare professionals and people with diabetes mellitus at home.

**(a) (2) Technological characteristics of the device.**

This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-glucose with recovery on the test systems in the range typically considered normal, fasting glucose for a non-diabetic person. This solution has been optimized to simulate the response of whole blood on the blood glucose test systems manufactured by AgaMatrix and utilizing the WaveSense family of blood glucose test strips. The solution contains no hazardous, human or animal derived components.

**(b) (1) Summary of non-clinical tests submitted with the premarket notification for the device.**

Tests were conducted to verify specific performance requirements:

- a) Closed bottle stability (Shelf-life)
- b) Stability after opening (Use-life)
- c) Transport Stability
- d) Test response

**(b) (2) Summary of clinical tests submitted with the premarket notification for the device.**

N/A

**(b) (3) Conclusions drawn from the clinical and non-clinical trials.**

Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence.



## DEPARTMENT OF HEALTH &amp; HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Bionostics, Inc.  
c/o Mr. Randy Byrd  
Chief Technical Officer  
7 Jackson Road  
Devens, MA 01434

SEP 19 2011

Re: k112356

Trade Name: Glucose Meter-Check Control Solution for AgaMatrix

Regulation Number: 21 CFR 862.1660

Regulation Name: Quality control material

Regulatory Class: Class I, reserved

Product Codes: JJX

Dated: August 15, 2011

Received: August 16, 2011

Dear Mr. Byrd,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Courtney H. Lias, Ph.D.  
Director  
Division of Chemistry and Toxicology  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## **Indications for Use**

510(k) Number: **K 112356**

Device Name: Glucose Meter-Check® Control Solution for AgaMatrix

Indications for Use: The Glucose Meter-Check Control Solution for AgaMatrix is intended for use to verify the performance and correct operation of the AgaMatrix blood glucose monitoring test systems utilizing the WaveSense family of blood glucose test strips. Glucose Meter-Check Control Solution for AgaMatrix is intended for use by healthcare professionals and people with diabetes mellitus at home.

**For *In Vitro* Diagnostic Use**

Prescription Use   
(Part 21 CFR 801 Subpart D)

AND/OR      Over-The-Counter Use   
(21 CFR 801 Subpart C)

**(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)**

---

Concurrent of CDRH, Office of Device Evaluation (OIVD)



Division Sign-Off  
Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K 112356

Page 1 of 1